Skip to content

  • Home
  • About us
    • The Company
    • Board of Directors
    • Management team
  • Partnering
    • Intellectual Property
  • Research and Development
    • Product portfolio
      • CellProtect
    • Technology
      • Natural killer (NK) cells
      • Mesenchymal cells
  • News
  • In media
  • Contact

First patient included, the first clinical batch of CellProtect is manufactured and stored frozen at Vecura, Karolinska University Hospital.

Published on September 19, 2014January 26, 2018 by cellprotect

Post navigation

Previous MPA approves the significant amendment and the change of sponsor to the phase I/II clinical investigation of CellProtect.
Next Patent is granted in People’s Republic of China and U.S.A for NK cell expansion, large scale closed culturing system.

Latest news

  • CellProtect Nordic Pharmaceuticals AB receives funding from Vinnova November 22, 2018
  • CellProtect Nordic Pharmaceuticals AB participates in the SWElife’s project on Advanced Therapy Medicinal Products (ATMPs) November 12, 2018
  • Patent is granted in Korea for Expansion of NK cells. June 25, 2018
  • Agneta Edberg to the Board of CellProtect Nordic Pharmaceuticals AB May 7, 2018
  • Swedish cell therapy candidate CellProtect has received orphan drug designation for the treatment of multiple myeloma January 29, 2018

Useful links

  • Karolinska Center for Cell Therapy
  • BOOSTB4)
  • Flemingsberg Science
  • AdBIOPRO

VISITING ADDRESS:

Hälsovägen 7, Novum
Floor 4, Elevator G
SE-141 57 HUDDINGE
SWEDEN

CONTACT INFOMATION:

KARIN MELLSTRÖM
Phone: +46 07 230 8002
E-POST: info@cellprotect.se

Create a website or blog at WordPress.com